Orthopedics
Conference Coverage
Predicting functional outcome after pediatric osteomyelitis
MADRID – The 0-10 scoring system identifies the small minority of patients who need long-term follow-up.
Conference Coverage
For vertebral osteomyelitis, early switch to oral antibiotics is feasible
VIENNA – Many patients with pyogenic vertebral osteomyelitis may have an alternative to IV antibiotics during their treatment course.
Conference Coverage
Think twice before recommending partial meniscectomy
LAS VEGAS – Patients with knee osteoarthritis and a meniscal tear who underwent arthroscopic partial meniscectomy subsequently experienced...
Conference Coverage
For bone and joint infections, oral antibiotics match IV, cost less
For bone and joint infections, oral antibiotics are as good as IV antibiotics and cost much less.
From the Journals
No benefit found for routine inpatient rehab after knee replacement
Inpatient rehabilitation did not provide a superior recovery across a range of outcomes for people who are well enough to be discharged to a...
News
Antibiotic prophylaxis for artificial joints
Is there compelling evidence to justify giving antibiotic prophylaxis for dental procedures to patients with prosthetic joints?
From the Journals
Perioperative infliximab does not increase serious infection risk
The timing of a last dose of infliximab prior to elective knee or hip replacement surgery does not appear to affect the 30-day risk of serious...
Conference Coverage
Bariatric surgery or total joint replacement: which first?
NEW ORLEANS – Encourage obese patients who need a total hip or knee replacement to undergo bariatric surgery beforehand, not after.
Conference Coverage
VIDEO: Biologics: Proposed guideline addresses perioperative management
Biologic agents should be stopped prior to elective total knee or hip arthroplasty in patients with rheumatic diseases, according to a draft...
Conference Coverage
Continue DMARDs, biologics in RA surgery patients
WASHINGTON - The perioperative use of disease-modifying antirheumatic drug monotherapy or combined therapy with methotrexate and tumor necrosis...
From the Journals
Anti–nerve growth factor drug has long-term OA pain benefit, but unclear safety
Treatment for a year with the human anti–nerve growth factor monoclonal antibody fulranumab provided pain relief and functional benefits to...